If the newsletter is not displayed properly, please visit our website >>> |
 AACR-NCI-EORTC
|
October 26-30.2017 in Philadelphia |
EPO will join the AACR-NCI-EORTC International Conference "Molecular Targets and Cancer Therapeutics" 2017 in Philadelphia, PA, between October 26-30.2017. If you are interested in special approaches or technologies of EPO, or if you want to talk to our CEO Dr. Jens Hoffmann, you are kindly invited to meet him at our two posters:
Poster #A005 Drug screening in patient-derived xenografts from acute myeloic leukemia and non-Hodgkin's lymphoma shows correlation with chemotherapy resistance in patients.
The poster will be presented in Poster Session A "Animal Models" on Saturday October 28, 2017 12:30 - 4:00 pm In Hall E, Pennsylvania Convention Center, Poster Board number 5; Abstract # 270
and
Poster #A006 Preclinical tumor models in humanized mice for translational immuno-oncology research.
The poster will be presented in Poster Session A "Animal Models" on Saturday October 28, 2017 12:30 - 4:00 pm In Hall E, Pennsylvania Convention Center, Poster Board number 6; Abstract # 272
The Abstracts of both posters can be read at our homepage http://www.epo-berlin.com/epo-news.html.
We are locking forward to meet you there.
Jens Hoffmann (CEO) EPO GmbH Berlin Buch | |
|
For more informations visit our Web site: www.epo-berlin.com or contact jens.hoffmann@epo-berlin.com |
|
Impress: EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH Robert-Rössle-Straße 10, Haus 82 13125 Berlin Germany Amtsgericht Charlottenburg,Sitz Berlin, HRB 61814 If you no longer wish to receive this newsletter, please click on unsubscibe.
|
Copyright:EPO GmbH© 2017 | |